[{"orgOrder":0,"company":"Citius Oncology","sponsor":"TenX Keane Acquisition","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Merger","leadProduct":"Denileukin Diftitox","moa":"Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Citius Oncology \/ TenX Keane Acquisition","highestDevelopmentStatusID":"15","companyTruncated":"Citius Oncology \/ TenX Keane Acquisition"},{"orgOrder":0,"company":"Citius Oncology","sponsor":"AmerisourceBergen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Agreement","leadProduct":"Denileukin Diftitox","moa":"Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Citius Oncology","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Citius Oncology \/ AmerisourceBergen","highestDevelopmentStatusID":"15","companyTruncated":"Citius Oncology \/ AmerisourceBergen"}]

Find Clinical Drug Pipeline Developments & Deals by Citius Oncology

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Under the agreement, Cencora will execute the distribution process of Lymphir (denileukin diftitox). It is being indicated for the treatemnt of Stage I-III cutaneous T-cell lymphoma.

                          Product Name : Lymphir

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          July 15, 2025

                          Lead Product(s) : Denileukin Diftitox

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : AmerisourceBergen

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lymphir (denileukin diftitox) is a specially engineered IL-2- diphtheria toxin fusion protein made using recombinant DNA technology for the treatment of cutaneous T-cell lymphoma.

                          Product Name : Lymphir

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          August 12, 2024

                          Lead Product(s) : Denileukin Diftitox

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : TenX Keane Acquisition

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank